YMN-A02 100μg
2026(889)
Phase 1 mab active
Quick answer
YMN-A02 100μg for Hepatocellular Carcinoma is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Hepatocellular Carcinoma
- Phase
- Phase 1
- Modality
- mab
- Status
- active